Target intelligence / Profile preview

Survival of motor neuron 2, centromeric (SMN2)

Target
SMN2
Molecular classification
Gene (protein coding), Genetic modifier, RNA-binding protein gene, Spliceosomal protein gene
01

Overview

SMN2 (Survival of motor neuron 2, centromeric) is a protein-coding gene located on chromosome 5q13 as part of a 500 kb inverted duplication region. It is nearly identical to its paralog SMN1, differing by only a single critical nucleotide (C to T transition) in exon 7 that functions as an exon splice enhancer. This single nucleotide difference has profound functional consequences: while SMN1 produces predominantly full-length functional SMN protein, SMN2 generates approximately 80-90% truncated, unstable protein (SMNΔ7) that lacks exon 7 and is rapidly degraded, with only 10-20% of transcripts producing full-length functional protein. The SMN protein encoded by SMN2 has the chemical formula C₁₃₉₄H₂₁₅₄O₄₃₈N₃₈₄S₁₃ and localizes to both cytoplasm and nucleus, where it concentrates in subnuclear structures called gems near Cajal bodies. The protein contains GEMIN2-binding, Tudor, and YG-Box domains and forms the core of the SMN complex, which serves as the primary cellular machinery for assembling small nuclear ribonucleoproteins (snRNPs), the essential building blocks of the spliceosome. While mutations in SMN2 itself do not cause disease (unlike SMN1 mutations which cause spinal muscular atrophy), SMN2 functions as a critical genetic modifier of SMA severity. Humans typically have 1-2 copies of SMN2, though copy numbers can range up to 8, and higher copy numbers correlate with increased SMN protein production and milder disease phenotypes. This relationship makes SMN2 an important therapeutic target, as strategies to increase functional SMN protein production from SMN2 can compensate for SMN1 deficiency. The gene produces multiple transcript variants, but only the full-length isoform d is functionally stable, while other variants are quickly degraded.

Other names
Survival Motor Neuron 2SMN2 geneCentromeric copy of SMNSurvival of motor neuron 2
02

Mechanism of action

Splice modulation - therapies aim to increase the proportion of full-length SMN protein produced from SMN2 by modifying exon 7 splicing. Gene compensation - SMN2 acts as a natural backup gene producing approximately 10-15% of functional SMN protein. Copy number-dependent protein production - higher SMN2 copy numbers correlate with increased SMN protein levels and less severe disease.

03

Biological functions

Small nuclear ribonucleoprotein (snRNP) assembly and biogenesisPre-mRNA splicing regulationSpliceosome assemblyMotor neuron maintenance and survivalTranscriptional regulationCellular traffickingTelomerase regenerationRNA-DNA hybrid resolution (R-loop resolution)Axon and dendrite developmentMessenger RNA processing
04

Disease associations

Spinal muscular atrophy (SMA) - genetic modifier determining disease severityNeurodegenerative disease - motor neuron degenerationThe gene itself does not cause disease when mutated, but modifies disease severity caused by SMN1 mutations
05

Safety considerations

SMN2 copy number variability between individuals (ranging from 1 to 8 copies) affects therapeutic response predictionSMN2 copy number is less predictive of prognosis than age of onset and functional abilities in some casesTissue-specific SMN requirements vary - motor neurons appear particularly sensitive to SMN deficiency while muscle tissue can function normally with reduced SMN levelsThe complexity and repetitiveness of the genomic region makes it prone to rearrangements and deletionsGene conversion events between SMN1 and SMN2 can lead to varying copy numbers
06

Biomarkers

SMN2 copy number - correlates inversely with disease severity in spinal muscular atrophy (higher copy numbers associated with milder phenotypes)SMN protein levels in tissues, particularly spinal cordFull-length SMN transcript levels versus truncated (Δ7SMN) transcriptsThe ratio of full-length to truncated SMN protein (approximately 10-20% full-length, 80-90% truncated from SMN2)

Beyond the preview

Go deeper on Survival of motor neuron 2, centromeric (SMN2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Survival of motor neuron 2, centromeric (SMN2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call